The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon
- 1 December 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 117 (6) , 751-758
- https://doi.org/10.1111/j.1365-2133.1987.tb07356.x
Abstract
Fifteen patients with primary Raynaud''s phenomenon received captopril 25 mg or placebo, three times daily for 6 weeks, in a randomized double-blind cross-over study. Compared with palcebo, captopril produced a significant improvement in cutaneous blood flow but did not alter the frequency or severity of attacks of Raynaud''s phenomenon.This publication has 21 references indexed in Scilit:
- ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: PAST, PRESENT, AND BRIGHT FUTUREThe Lancet, 1985
- Photoplethysmography of the Distal Pulp in the Assessment of the Vasospastic HandAngiology, 1985
- Treatment with captopril for peripheral ischaemia induced by ergotamine.BMJ, 1984
- Behandlung des Raynaud-Syndroms mit CaptoprilDeutsche Medizinische Wochenschrift (1946), 1984
- INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROMEThe Lancet, 1983
- Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.BMJ, 1982
- CaptoprilNew England Journal of Medicine, 1982
- Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2)British Journal of Dermatology, 1982
- Relationships between the kallikrein-kinin and prostaglandin systemsLife Sciences, 1979
- The two‐period cross‐over clinical trial.British Journal of Clinical Pharmacology, 1979